MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia

Giovanni Marconi, Annalisa Talami, Maria Chiara Abbenante, Chiara Sartor, Sarah Parisi, Jacopo Nanni, Luca Bertamini, Simone Ragaini, Matteo Olivi, Stefano de Polo, Gianluca Cristiano, Maria Chiara Fontana, Maria Teresa Bochicchio, Emanuela Ottaviani, Mario Arpinati, Mariarosaria Sessa, Carmen Baldazzi, Lucia Caso, Nicoletta Testoni, Michele BaccaraniFrancesca Bonifazi, Giovanni Martinelli, Stefania Paolini, Michele Cavo, Cristina Papayannidis, Antonio Curti

Research output: Contribution to journalArticlepeer-review

Abstract

INTRODUCTION: Clinical response and chemosensitivity of relapse or refractory AML patients were evaluated after rescue and bridge-to-transplant MEC (mitoxantrone, etoposide, and cytarabine) regimen.

METHODS AND PATIENTS: Fifty-five consecutive AML patients were treated with MEC from 2009 to 2018. Chemosensitivity was evaluated by WT1 quantification.

RESULTS: 27/55 patients (49.1%) had AML resistant to induction and 28/55 patients (50.9%) had AML relapse. 25/55 patients (45.5%) achieved a CR after one course of MEC, and 12 patients (21.8%) achieved WT1 negativity. In 12 patients, a second MEC was administered. Four out of 12 patients improved significantly their response with the 2nd MEC. MEC was an effective bridge to transplant, 32/55 patients (58.2%) received an allogenic stem cell transplant. Median overall survival (OS) from MEC was 455 days (95% CI 307-602 days.); patient with WT1 negative CR had the best OS (P<.000).

CONCLUSION: WT1 is a useful marker of chemosensitivity after MEC as rescue and bridge-to-transplant therapy.

Original languageEnglish
Pages (from-to)47-55
Number of pages9
JournalEur. J. Haematol.
Volume105
Issue number1
DOIs
Publication statusPublished - Jul 2020

Fingerprint Dive into the research topics of 'MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia'. Together they form a unique fingerprint.

Cite this